Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes

Biomol Biomed. 2023 Mar 16;23(2):189-190. doi: 10.17305/bb.2022.8874.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Camptothecin / therapeutic use
  • Female
  • Humans
  • Immunoconjugates* / adverse effects

Substances

  • sacituzumab govitecan
  • Camptothecin
  • Immunoconjugates
  • Antibodies, Monoclonal, Humanized